
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Oxytocin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Shalvata Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oxytocin is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
March 27, 2024
Lead Product(s) : Oxytocin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Shalvata Mental Health Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Brizo
Therapeutic Area : Urology
Study Phase : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brizo is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Hyperplasia.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 07, 2022
Lead Product(s) : Brizo
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Penicillin Allergy in Shfayim Clinic
Details : Amoxicillin is a Antibiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Penicillin Hypersensitivity.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 17, 2018
Lead Product(s) : Amoxicillin Trihydrate
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Aboca
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.
Details : This drug candidate is currently being evaluated in phase IV clinical studies for the treatment of Cough.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 24, 2013
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Aboca
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : HaEmek Medical Center, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
Details : Capecitabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2012
Lead Product(s) : Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : HaEmek Medical Center, Israel
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
Details : Adalimumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colitis, Ulcerative.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 19, 2011
Lead Product(s) : Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Erlotinib
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Erlotinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2010
Lead Product(s) : Erlotinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RoActemra (Tocilizumab) is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : RoActemra
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 23, 2010
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vitamin D
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Vitamin D and Inflammatory Cytokine Levels After Acute Myocardial Infraction (MI)
Details : Vitamin D is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acute Coronary Syndrome.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 04, 2010
Lead Product(s) : Vitamin D
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : Meir Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
A Double-Blind Study to Evaluate the Effect of Femarelle® on Menopausal on Vasomotor Symptoms
Details : Femarelle is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Menopause.
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
February 05, 2010
Lead Product(s) : Femarelle
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : Se-cure Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
